Pliant Therapeutics Q3 net loss narrows to $26.3M; BEACON-IPF close out near completion

PLIANT THERAPEUTICS, INC.

2025-Q3 EPS reported -$2.05 vs consensus -$0.53 ▼ miss (-283.8%)

Net loss $26.3M vs $57.8M YoY; R&D expense fell to $17.9M from $47.8M.
Cash, equivalents and short-term investments $243.3M as of Sept 30, 2025.
Phase 1 trial of PLN-101095 completed enrollment; data expected Q4 2025.
BEACON-IPF close out activities to be completed in Q4 2025.
Voluntary prepayment of Oxford Finance LLC loan completed in October 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.